Trazodone Global Regulatory Status: FDA Approval, International Labels, and Post-Market Safety

FDA Approval History and Original Indication

The U.S. Food and Drug Administration approved trazodone hydrochloride on September 29, 1981, under NDA 018207, with Bristol-Myers (later Bristol-Myers Squibb) as the original sponsor marketing it under the brand name Desyrel [1]. The approved indication was major depressive disorder (MDD) in adults. Trazodone became available at a time when tricyclic antidepressants dominated prescribing, and its distinct pharmacologic profile offered a different side-effect burden, particularly fewer anticholinergic effects [2].

The drug's mechanism classifies it as a serotonin antagonist and reuptake inhibitor, or SARI. It blocks 5-HT2A receptors and inhibits serotonin reuptake, but at lower doses its antihistaminic (H1) and alpha-1 adrenergic blocking properties produce sedation rather than antidepressant effects [3]. This dose-dependent pharmacology explains why clinicians began prescribing trazodone at sub-antidepressant doses (25 to 100 mg) for insomnia shortly after its launch.

The FDA's Drugs@FDA database lists multiple approved generics under ANDAs filed after Desyrel's patents expired. By the mid-1990s, generic trazodone dominated the market. A modified-release formulation (Oleptro, later discontinued) received approval in 2010 under NDA 022411, designed for once-daily dosing at 150 mg or 300 mg [1].

Current FDA Labeling and Boxed Warning

Trazodone's current prescribing information carries the class-wide boxed warning that the FDA mandated for all antidepressants in 2004 (expanded in 2007). The warning states that antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults aged 18 to 24 during initial treatment [4]. Short-term studies did not show an increase in suicidality risk in adults older than 24, and adults aged 65 and older showed a reduced risk [4].

The label specifies a starting dose of 150 mg/day in divided doses for depression, with increases of 50 mg/day every three to four days. The maximum recommended dose is 400 mg/day for outpatients and 600 mg/day for inpatients [1]. No dosing guidance for insomnia appears in the label because no sleep indication has been approved.

Key warnings in the current label include serotonin syndrome (especially with concomitant serotonergic agents), QT prolongation at supratherapeutic doses, orthostatic hypotension, and priapism [1]. The priapism warning is specific to trazodone among antidepressants. Surgical intervention has been required in some reported cases, and permanent erectile dysfunction has occurred [5].

Off-Label Insomnia Use and Regulatory Gap

Trazodone is the most commonly prescribed medication for insomnia in the United States, yet it holds no FDA approval for any sleep disorder. A 2014 analysis published in the Journal of Clinical Psychiatry found that trazodone accounted for roughly half of all antidepressant prescriptions written primarily for insomnia [6]. Mendelson's 2005 review in the same journal examined the limited evidence base supporting this practice, noting that most positive trials involved small sample sizes and short durations, typically two weeks or less [7].

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline on pharmacologic treatment of chronic insomnia gave trazodone a "WEAK AGAINST" recommendation, citing insufficient evidence for efficacy and concerns about next-day sedation [8]. Despite this, prescribing has not declined. The disconnect between clinical practice and regulatory status is notable. No manufacturer has pursued a formal insomnia indication, likely because generic status removes any financial incentive for the large Phase III trials the FDA would require.

The FDA has not taken enforcement action against off-label prescribing of trazodone for insomnia, consistent with its general position that licensed physicians may prescribe approved drugs for unapproved uses based on clinical judgment. The agency's 2023 draft guidance on off-label communication reiterated that manufacturers cannot promote unapproved uses [9].

European Regulatory Status

Trazodone does not have a centralized European Medicines Agency (EMA) authorization. Instead, it is approved at the national level in individual EU member states through their own regulatory agencies [10]. In Italy, where trazodone was originally developed by Angelini Pharma, it holds marketing authorization under the brand name Trittico. The Italian Medicines Agency (AIFA) lists the approved indication as major depressive episodes with or without anxiety [10].

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) lists trazodone under the brand Molipaxin, approved for depressive illness with or without anxiety [11]. The Summary of Product Characteristics (SmPC) mirrors FDA labeling on key warnings but includes additional text on QT prolongation risk in patients with pre-existing cardiac conditions. The MHRA issued a Drug Safety Update in 2011 noting rare cases of cardiac arrhythmia associated with trazodone [11].

Germany's Federal Institute for Drugs and Medical Devices (BfArM) approved trazodone for depression, with the SmPC noting that the sedative properties may be therapeutically useful in patients with insomnia-predominant depression. This labeling stops short of a standalone insomnia indication but acknowledges the sedative effect more explicitly than the FDA label [10].

Regulatory Status in Asia-Pacific and Other Regions

Japan's Pharmaceuticals and Medical Devices Agency (PMDA) approved trazodone under the brand name Desyrel in 1991 for the treatment of depression [12]. The approved daily dose range in Japan is 75 to 200 mg, lower than the U.S. maximum, reflecting body-weight-based dosing conventions common in Japanese regulatory practice.

Health Canada approved trazodone for major depressive episodes, with the Canadian product monograph closely tracking FDA labeling [13]. The Therapeutic Goods Administration (TGA) in Australia lists trazodone on the Australian Register of Therapeutic Goods for depressive illness [14]. Both agencies carry similar boxed or prominent warnings about suicidality risk in younger patients.

In Latin America, trazodone is widely available. Brazil's ANVISA and Mexico's COFEPRIS have approved it for depression under various brand names. South Africa's SAHPRA (formerly MCC) likewise lists trazodone for depressive disorders. In most of these jurisdictions, the prescribing information mirrors the FDA or EMA national-level labeling with minor local adaptations [10].

Post-Market Safety Surveillance

The FDA Adverse Event Reporting System (FAERS) database contains thousands of reports associated with trazodone since its approval. The most clinically significant signal remains priapism. A 2019 pharmacovigilance review using the FDA Sentinel System identified an incidence of approximately 1 in 6,000 to 1 in 8,000 male patients prescribed trazodone, consistent with earlier estimates from voluntary reporting [5].

Serotonin syndrome reports have increased over the decades, paralleling the rise in polypharmacy with SSRIs, SNRIs, and other serotonergic drugs [15]. The FDA issued a 2016 Drug Safety Communication reinforcing the risk of serotonin syndrome when trazodone is combined with other serotonergic medications, including tramadol and certain migraine drugs (triptans) [16].

QT prolongation has emerged as a lower-frequency but high-severity signal. Post-market reports and a 2013 analysis showed that trazodone at doses exceeding 300 mg/day was associated with QTc interval increases of 10 to 15 ms [17]. The label was updated to reflect this risk. Patients with pre-existing QT prolongation, those taking other QT-prolonging drugs, and those with hypokalemia or hypomagnesemia are at greatest risk.

Falls and fractures represent another post-market concern, particularly in elderly patients. Trazodone's alpha-1 blockade causes orthostatic hypotension, and its sedative effects compound fall risk. A 2018 cohort study published in JAMA Internal Medicine found that trazodone use in adults over 65 was associated with a 20% increased risk of hip fracture compared to non-use (adjusted HR 1.20 to 95% CI 1.08 to 1.34) [18].

Scheduling, Controlled-Substance Status, and Abuse Potential

Trazodone is not a scheduled controlled substance in the United States, United Kingdom, Canada, or Australia [1][11][13][14]. The Drug Enforcement Administration (DEA) does not classify it under the Controlled Substances Act. This distinguishes trazodone from benzodiazepine and Z-drug hypnotics (Schedule IV), which is one reason clinicians prefer it for insomnia in patients with substance use histories.

Abuse potential is considered low. A 2020 systematic review found no strong evidence of trazodone dependence or withdrawal syndrome comparable to benzodiazepines, though abrupt discontinuation after prolonged use at high doses can produce rebound insomnia and anxiety [19]. The FDA label recommends gradual dose reduction when discontinuing.

Recent and Pending Regulatory Actions

No new FDA regulatory actions specific to trazodone are pending as of May 2025. The most recent labeling revision addressed minor formatting changes and updated the Medication Guide. The FDA's ongoing class-wide review of antidepressant suicidality data has not produced changes beyond the existing boxed warning [4].

In Europe, the Pharmacovigilance Risk Assessment Committee (PRAC) included trazodone in its 2024 periodic review of older antidepressants but issued no new safety signals or referral procedures [10]. National-level SmPCs continue to be updated independently, with the most active revisions occurring in Italy and Germany.

Interest in new trazodone formulations persists. A once-nightly extended-release trazodone product (Oleptro) received FDA approval in 2010 but was commercially discontinued in 2016 due to low market uptake [1]. No current applications for novel trazodone formulations appear in the FDA's CDER pipeline database.

The regulatory gap between trazodone's off-label insomnia use and its approved indication for depression remains the defining feature of this drug's regulatory profile. Prescribers should document clinical rationale when using trazodone for sleep, start at the lowest effective dose (typically 25 to 50 mg), and monitor for orthostatic hypotension and next-day sedation, especially in patients over 65 [8].